Literature DB >> 27785939

Vasorelaxant Action of the Chloroform Fraction of Orthosiphon stamineus via NO/cGMP Pathway, Potassium and Calcium Channels.

Mun Fei Yam1,2, Chu Shan Tan2, Mariam Ahmad2, Shibao Ruan1.   

Abstract

Orthosiphon stamineus Benth. (Lamiaceae) is an important plant in traditional folk medicine that is used to treat hypertension and kidney stones. In humans, this plant has been tested as an addition regiment for antihypertensive treatment. Among the treatments for hypertension, O. stamineus had been to have diuretic and vasorelaxant effects in animal models. There is still very little information regarding the vasorelaxant effect of O. stamineus. Therefore, the present study was designed to investigate the vasorelaxant activity and mechanism of action of the fractions of O. stamineus. The vasorelaxant activity and the underlying mechanisms of the chloroform fraction of the 50% methanolic extract of O. stamineus (CF) was evaluated on thoracic aortic rings isolated from Sprague Dawley rats. CF caused relaxation of the aortic ring pre-contracted with phenylephrine in the presence and absence of endothelium, and pre-contracted with potassium chloride in endothelium-intact aortic ring. In the presence of endothelium, both indomethacin (a nonselective cyclooxygenase inhibitor) and [Formula: see text]-[1,2,4]Oxadiazolo[4,3-[Formula: see text]]quinoxalin-1-one (ODQ, selective soluble guanylate cyclase inhibitor) had a small effect on the vasorelaxation response. On the other hand, in the presence of Nω-nitro-L-arginine methyl ester (L-NAME, nitric oxide synthase inhibitor), methylene blue (cyclic guanosine monophosphate lowering agent), tetraethylammonium ([Formula: see text], nonselective calcium activator [Formula: see text] channel blocker), 4-aminopyridine (4-AP, voltage-dependent [Formula: see text] channel blocker), barium chloride ([Formula: see text], inwardly rectifying [Formula: see text] channel blocker), glibenclamide (nonspecific ATP-sensitive [Formula: see text] channel blocker), atropine (muscarinic receptor blocker) and propranolol (β-adrenergic receptor blocker), the vasorelaxant effect significantly reduced the relaxation stimulated by CF. CF was also found to be active in reducing [Formula: see text] release from the sarcoplasmic reticulum and blocking calcium channels.

Entities:  

Keywords:  Orthosiphon stamineus; Potassium and Calcium Channels; Vasorelaxation

Mesh:

Substances:

Year:  2016        PMID: 27785939     DOI: 10.1142/S0192415X16500798

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  5 in total

Review 1.  Exploration of Lamiaceae in Cardio Vascular Diseases and Functional Foods: Medicine as Food and Food as Medicine.

Authors:  Ishani Chakrabartty; Yugal Kishore Mohanta; Amilia Nongbet; Tapan Kumar Mohanta; Saurov Mahanta; Nibedita Das; Muthupandian Saravanan; Nanaocha Sharma
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

2.  Mechanism of vasorelaxation induced by 3'-hydroxy-5,6,7,4'-tetramethoxyflavone in the rats aortic ring assay.

Authors:  Chu Shan Tan; Mun Fei Yam
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

Review 3.  Overview of the Microenvironment of Vasculature in Vascular Tone Regulation.

Authors:  Yean Chun Loh; Chu Shan Tan; Yung Sing Ch'ng; Zhao Qin Yeap; Chiew Hoong Ng; Mun Fei Yam
Journal:  Int J Mol Sci       Date:  2018-01-02       Impact factor: 5.923

Review 4.  Review of Natural Resources With Vasodilation: Traditional Medicinal Plants, Natural Products, and Their Mechanism and Clinical Efficacy.

Authors:  Fei Tang; Hong-Ling Yan; Li-Xia Wang; Jin-Feng Xu; Cheng Peng; Hui Ao; Yu-Zhu Tan
Journal:  Front Pharmacol       Date:  2021-04-01       Impact factor: 5.810

5.  Investigation into the Antihypertensive Effects of Diosmetin and Its Underlying Vascular Mechanisms Using Rat Model.

Authors:  Taseer Ahmad; Adil Javed; Taous Khan; Yusuf S Althobaiti; Aman Ullah; Farooq M Almutairi; Abdul Jabbar Shah
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.